SAN FRANCISCO, Oct. 04, 2022 (GLOBE NEWSWIRE) — Olema Pharmaceuticals, Inc. (“Olema,” “Olema Oncology” or the “Company,” Nasdaq: OLMA), a clinical-stage biopharmaceutical firm centered on the invention, growth, and commercialization of focused therapies for girls’s cancers, immediately introduced that the Company granted inventory choices to 4 new workers to buy an mixture of 58,300 shares of the Company’s widespread inventory, efficient as of October 3, 2022. These awards have been authorized by the Compensation Committee of Olema’s Board of Directors and granted below the Company’s 2022 Inducement Plan, with a grant date of October 3, 2022, as an inducement materials to the brand new worker getting into into employment with Olema, in accordance with Nasdaq Listing Rule 5635(c)(4).
The inventory choices vest over 4 years, with 25 p.c vesting on the primary anniversary of the vesting graduation date for such worker and the rest vesting in 36 equal month-to-month installments over the next three years, topic to the worker being constantly employed by Olema as of such vesting dates. The inventory choices have a 10-year time period and an train value of $2.91 per share, equal to the final reported sale value of the Company’s widespread inventory as reported by Nasdaq on October 3, 2022. The inventory choices are topic to the phrases of the Olema Pharmaceuticals, Inc., 2022 Inducement Plan.
Olema is offering this info in accordance with Nasdaq Listing Rule 5635(c)(4).
About Olema Oncology
Olema Oncology is a clinical-stage biopharmaceutical firm centered on the invention, growth and commercialization of focused therapies for girls’s cancers. Olema’s lead product candidate, OP-1250, is an orally obtainable small molecule with mixed exercise as each an entire estrogen receptor (ER) antagonist (CERAN) and a selective ER degrader (SERD). It is presently being evaluated as a single agent in an ongoing Phase 1/2 scientific trial, and in Phase 1b mixture with palbociclib, in sufferers with recurrent, domestically superior or metastatic ER-positive (ER+), human epidermal progress issue receptor 2-negative (HER2-) breast most cancers. Olema is headquartered in San Francisco and has operations in Cambridge, Massachusetts.
Contact:
Shane Kovacs, COO and CFO
[email protected]
